用户名: 密码: 加入会员
   


选择字号:   本文共阅读 9534 次 更新时间: 2011-04-28 15:29:32      添加到我的收藏
当前位置:首页 > 中战资讯 > 阅读文章
有潜力的免疫学原始创新科技被特许在中国合作
·中战会

    纽约、2011年4月28日,中国战略与管理研究会中战蓝盟投资有限公司和哥伦比亚大学今天宣布:双方签署了哥伦比亚大学某些系列知识产权的全球专用特许和科研的协议,此项系列知识产权为寻求人体自身免疫病和其它多种免疫相关疾病的诊断和治疗的新型途径奠定了基础。
    人体免疫系统的一个主要功能是它的“辨别自我和非我”的能力, 即能够区别对待抗自身组织器官的对机体有害的自身免疫反应和机体正常进行的抗感染与抗肿瘤的免疫反应。当这种辨别机能被中断或出故障时,免疫系统就会产生自身攻击,从而导致例如一型糖尿病、多发性硬化症、甲状腺病、白癜风、牛皮癣和风湿性关节炎等多种自身免疫病。特异性抑制对机体有害的抗自身的免疫反应却不防碍免疫系统的其它正常功能是现代医学在治疗自身免疫病和控制器官移植的排异反应的医学实践中期望达到的终极目标。理解免疫系统如何达到“自我非我辨别”的机制则是达到这一终极目标所应必备的知识。然而,尽管半个世纪以来免疫系统如何“辨别自我非我”始终被视为现代科学的一个核心难题,与此有关的机制迄今依然不明。
    最近,哥伦比亚大学医学中心的本项目首席科学家,华裔免疫学家蒋红博士及其合作者,世界著名免疫学家伦纳德•蔡斯博士在阐明免疫系统如何“辨别自我非我”的科研上取得了重大科学突破,极大地推进了对这一难题的理论和实践层面上的理解。蒋红和蔡斯提出了一个免疫系统“自我非我辨别”的理论模式,被命名为《外周T细胞免疫调节亲合力模式》。 这一理论模式提供了如何在医学实践中选择性靶向抑制那些可以导致自身免疫病的T细胞的新型诊疗途径的理论基础。
    蒋红博士指出:“过去几十年来,控制自身免疫病的方法无一例外地应用全面降低免疫反应的途径。虽然这一治疗途径可以在某些方面缓解自身免疫病,却因对免疫系统的全面抑制而不可避免地损伤了机体正常进行的抗感染和抗肿瘤的免疫反应。”“我们目前更多地理解了能够辨别自我和非我的调节机制并发现了伴随着人类自身免疫病的导致自我非我辨别机制功能失调的细胞和分子缺陷。”蒋红和蔡斯博士正致力于研发准确安全瞄控纠正这一缺陷治疗患者而不损伤他们正常免疫功能的新型诊疗途径。
    哥伦比亚大学医学系主任唐•兰锥博士认为:“这一中国和哥伦比亚大学的合作项目预示着将对医学和全世界的人类健康产生重大影响。”
    “我们相信美国哥伦比亚大学的这一原始创新学说和相关科研”。中战蓝盟投资有限公司总裁、赴美签约团团长苏伟先生表示,“我们愿意承担因支持此项研究所产生的投资和管理上的风险。并将为人类健康生存,为促进中美两国在高科技领域的友谊与合作,为蒋红/蔡斯发明的商品化、工业化,并在世界范围内生产、销售、使用相关免疫生物产品和技术等做出不懈努力。”
    哥伦比亚大学医学中心:在生命科学领域,包括基础医学,临床前期和临床实践的研究和教学中,以及在对病患的诊治和护理中居国际领先地位。哥大医学中心包括医学院、公共卫生学院、牙医学院、护校、哥伦比亚大学研究生院的生物医学分院及其所属科研中心和研究所等。哥大医学中心代表着包括临床医生、科研人员、医疗专业人员、牙医、和医护人员在内的所有工作人员的辛勤工作,并培养着未来的领军人物。创建于1767年的哥大医学院是美国第一所具授予医学博士学位权的医科大学。在美国最领先的医学院中,哥大医学院是全美和纽约州最具规模的医学和科研中心。更多详情请查www.cumc.columbia.edu.
    
    Promising Technology in Immunology
    Licensed to Partnership in China

    
    NEW YORK, April 28, 2011 — China Institute of Strategy and Management Lanmeng Investment Co., Ltd., and Columbia University announced today that they have entered into research and license agreements, granting worldwide exclusive rights to a portfolio of certain Columbia intellectual property that may lay the foundation for new approaches in the diagnosis and treatment of a variety of human autoimmune diseases and a wide range of other human immunologic relevant disorders.
    
    A key feature of the human immune system is its ability to discriminate the immune responses against antigens from its own tissues and organs versus the immune responses against “nonself antigens,” which are those from any other organisms, such as infectious agents or tumors. When there is a disruption or breakdown of the mechanisms that enable this ability, the immune system attacks the body’s own tissues and organs, giving rise to autoimmune disorders such as type 1 diabetes, multiple sclerosis, thyroid disease, vitiligo, psoriasis, and rheumatoid arthritis. Specific control of such unwanted autoimmune responses without disabling normal function of the immune system during therapy is an ultimate goal in today’s medicine to treat autoimmune diseases, as well as to control rejection in organ transplantation. Accomplishing this goal requires detailed knowledge and understanding of how the immune system discriminates self from nonself, which has been considered a central conundrum in modern science for the last half century, and remained elusive.
    
    Recently, Dr. Hong Jiang, a Chinese native and lead scientist of this project, and her collaborator, a world-renowned immunologist, Dr. Leonard Chess of Columbia University Medical Center, have made a discovery that significantly advances the understanding of how immune cells make this discrimination. Jiang and Chess have posited a theoretical model for this self versus non-self discrimination that they call, “An Avidity Model of Peripheral T Cell Regulation.” The conceptual framework of this model provides a theoretical basis for how novel therapies can be designed to selectively target only the T cells that are harbingers of autoimmunity.
    
    “For decades, autoimmune diseases have been generally treated by nonspecifically reducing overall immune response. Although this approach may ameliorate some aspects of autoimmune disease, a major side effect of the current approaches is that by also inhibiting the normal immune responses, it inevitably damages the body’s ability to eradicate infectious diseases and tumors,” said Dr. Hong Jiang, “Now we have a better understanding of the specific mechanism of how regulatory T cells discriminate between ‘self’ and ‘non-self,’ and have discovered the cellular/molecular defect associated with human autoimmune diseases that leads the self/non-self discrimination process to go awry.” Drs. Jiang and Chess hope to develop novel therapeutic strategies that will specifically and safely identify and correct the defects in patients to treat their diseases without damaging the body’s normal anti-infection and anti-tumor immunity.
    
    “This collaboration between China and Columbia holds promise to be of great importance to medicine and to world health,” said Dr. Donald W. Landry, Chairman of Medicine at Columbia University’s College of Physicians and Surgeons.
    
    “We believe in this original and innovative science from Columbia University,” said Mr. Wei Su, CEO of the China Institute of Strategy and Management Lanmeng Investment Co., and the director of the Chinese delegate for signing the agreement. “We are willing to take the risk of investment and management in support of the research, for the extension of people's livelihoods and well-being, to promote Sino-US friendship and cooperation in the high-tech field and for commercialization, industrialization, worldwide manufacturing, use and distribution of the immune biologics and the technology that are based on the Jiang/Chess invention.”
    
    Columbia University Medical Center provides international leadership in basic, pre-clinical, and clinical research; in medical and health sciences education; and in patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Established in 1767, Columbia's College of Physicians and Surgeons was the first institution in the country to grant the M.D. degree and is among the most selective medical schools in the country. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest in the United States. For more information, please visit http://www.cumc.columbia.edu
    
    About Columbia Technology Ventures
    
    Columbia University's technology transfer office, Columbia Technology Ventures, manages Columbia's intellectual property portfolio and serves as the university's gateway for companies and entrepreneurs seeking novel technology solutions. Our core mission is to facilitate the transfer of inventions from academic research to outside organizations for the benefit of society on a local, national and global basis. For more information on Columbia Technology Ventures, please visit www.techventures.columbia.edu.
    


■ 本文责编: frank
□ 文章来源:中战会首发,转载请注明出处(http://www.cssm.org.cn)。
寄给好友:
在方框中输入电子邮件地址,多个邮件之间用半角逗号(,)分隔。
凡本网首发的所有作品,版权均属于作者本人和中国战略与管理网,网络转载请注明作者、出处并保持完整,纸媒转载请经本网书面授权。 凡本网注明“来源:XXX(非中国战略与管理网)”的作品,均转载自其它媒体,中国战略与管理网不拥有该文版权。转载目的在于传递更多信息,并不代表本网赞同其观点和对其真实性负责。若作者或版权人不愿被使用,请即指出,本网即予改正。